Breakthrough in Diabetes Treatment: Our New Fast-Acting Insulin Hits Clinical Milestone

We’re excited to announce that our innovative fast-acting insulin formulation has successfully completed Phase III clinical trials. This marks a significant milestone in our mission to improve the quality of life for individuals living with diabetes.

The trial results demonstrated a rapid onset of action, improved glycemic control, and reduced risk of hypoglycemia compared to current standard treatments. With regulatory submissions now underway, we’re one step closer to delivering a solution that supports better daily management for millions of patients.

Stay tuned as we prepare for global launch and further developments in our metabolic health portfolio.